OrganaBio expanded cell and gene therapy sample processing capacity by launching time-sensitive PBMC isolation and cryopreservation in San Diego at Excellos Labs. The local workflow is designed to reduce the typical logistics gap by isolating and cryopreserving PBMCs within about three to four hours of leukapheresis collection. OrganaBio said the San Diego facility supports average PBMC viability around 99.1% with recovery above 2.9 million cells per milliliter, emphasizing consistency across batches through standardized operating procedures and a unified quality system. For autologous and immunotherapy developers, the bottleneck is that delayed processing can degrade cell viability and function before cryopreservation. The added hub is intended to tighten timelines and reduce supply-chain risk for sponsors located in major West Coast cell and gene therapy clusters.